Vapotherm (VAPO) Tops Q1 EPS by 2c

Vapotherm (NYSE: VAPO) reported Q1 EPS of ($0.76), $0.02 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $11.98 million.

“We are pleased with our performance during the first quarter,” said Joe Army, President and CEO of Vapotherm. “We drove top line growth and exceeded our gross margin expectations. We expanded our body of clinical data and our new product development projects are tracking to plan. For the rest of 2019, our focus will be to drive adoption of Hi-VNI Technology and leverage the momentum we continue to build with the expansion of our salesforce and focus on the Emergency Department (ED). We are also excited about the potential future launch of multiple new products, including IntellO2™, and its compelling clinical data showing the value of our Hi-VNI Technology versus the current standard of care.”

GUIDANCE:

For fiscal 2019, we continue to expect revenue in the range of $49.0 million to $51.0 million, representing an anticipated year-over-year increase of between 16% to 20%.

In the second quarter of 2019, we expect revenue in the range of $11.8 million to $12.0 million.

For earnings history and earnings-related data on Vapotherm (VAPO) click here.

You May Also Be Interested In

• inTEST Corp (INTT) reported Q2 Revenue ; Offers Guidance
• Regal-Beloit (RBC) Tops Q1 EPS by 47c; offers guidance
• Oceanfirst Financial (OCFC) Reports In-Line Q2 EPS